The optical density was measured at 620 nm after removal and cooling to room temperature
FDA PCAC 2023 What this means practically for research dosage decisions: Doses above 1 mg/day are not supported by efficacy data and appear to produce diminishing returns
WADA Prohibition Status Based on WADAs prohibition categories: GLP3 likely falls under Section S0 (Non-Approved Substances) of the WADA Prohibited List, which includes: Any pharmacological substance not approved by governmental regulatory health authorities for human therapeutic use Drugs under preclinical or clinical development Substances without current regulatory approval from any health authority worldwide Implications for competitive athletes: Prohibited at all times (in-competition and out-of-competition) No Therapeutic Use Exemptions available for unapproved substances Use could result in anti-doping rule violations and sanctions Detection methods under development as clinical trials progress Research Classification: GLP3 is available exclusively for use in FDA-approved clinical trials under Investigational New Drug applications
Liu, K.-S., Mao, X.-D., Pan, F
Sulforaphane protects developing neural networks from VPA-induced synaptic alterations
Experimental mice got injections of the peptide 5 times a week, and the results showed that it suppressed the formation of neoplasms, decreased lungs metastases by 1,6 times, multiple tumors by 2 times, 3,7-fold increase of mice without breast tumors and decrease of mice with 6 or more tumors by 3 times
